ログイン

MEDICATION RELATED PROBLEMS.
33問 • 2年前
  • Quinn Karylle Fuentes
  • 通報

    問題一覧

  • 1

    No error, capacity to cause error

    Category A.

  • 2

    Error that did not reach the patient

    Category B.

  • 3

    Error that reach the patient but unlikely to cause harm (omissions considered to reach patient)

    Category C.

  • 4

    Error that reached the patient & could have necessitated monitoring and or intervention to preclude harm

    Category D.

  • 5

    Multivitamins was not ordered on admission

    Category C.

  • 6

    Regular release metoprolol was ordered to patient instead of extended-release

    Category D.

  • 7

    Error that could have caused temporary harm - Needs treatment or intervention

    Category E.

  • 8

    Antihypertensive as inadvertently omitted from the orders.

    Category E.

  • 9

    Error that could have cause temporary harm requiring initial prolonged hospitalization

    Category F.

  • 10

    Anticoagulant such as warfarin was ordered daily when the patient takes it every other day

    Category F.

  • 11

    Error that could have resulted into permanent harm

    Category G.

  • 12

    Immunosupressant medication was unintentionally ordered at ¼ of the dose

    Category G.

  • 13

    Error that could have necessitated intervention to sustain life

    Category H.

  • 14

    Anticonvulsant therapy was inadvertently omitted

    Category H.

  • 15

    Error that could have resulted in death

    Category I.

  • 16

    Beta blocker was not re-ordered post-operatively.

    Category I.

  • 17

    This allows the person who commits the error or the person who discover the error to report it without being associated with the error.

    Anonymous self reports.

  • 18

    This is the official written legal reports of a medication error as documented by the hospital staff.

    Incident reports.

  • 19

    This results to underreporting of the errors due to punitive action that might occur due to the report

    Incident reports.

  • 20

    This involves in depth analysis of a large number of individual errors or the purpose of identifying a common cause.

    Critical incident techniques.

  • 21

    it involves an observer accompanying the person who will give the medication and witnessing the administration of each dose.

    Distinguished observation.

  • 22

    obtained directly from patient given by the patient, family members or significant others or caregivers typically cannot be directly measure.

    Subjective.

  • 23

    Measurable and not influenced by memory, emotions, or prejudice

    Objective.

  • 24

    outlines what the practitioner thinks the patient’s problem is, based upon the subjective and objective information acquired

    Assessment.

  • 25

    Involves the action that needs to be taken to resolve any problems that have been identified

    Plan.

  • 26

    includes initiating, revising, or discontinuing treatment or ordering additional diagnostic tests.

    Plan.

  • 27

    It outlines the drug, dose, dosage form, schedule, route of ad- ministration, and duration of therapy should be included

    Plan.

  • 28

    clearly state the nature of the drug-related problem(s) à types of medication-related problems. This will include medical information both subjective and objective findings that indicate a drug-related problem

    Findings.

  • 29

    includes the pharmacist’s evaluation of the current situation (i.e., the nature, extent, type, and clinical significance of the problem). This part of the note should delineate the thought process that led to the conclusion that a problem did or did not exist and that an active intervention either was or was not.

    Assessment.

  • 30

    this should reflect the actions proposed (or already performed) to resolve the drug-related problem based upon the preceding analysis

    Resolution.

  • 31

    include questioning the patient, gathering laboratory data, and performing the ongoing physical assessments necessary to determine the effectiveness of the plan implemented to assure that it results in an optimal outcome for the patient.

    Monitoring.

  • 32

    Objective.

    Quantitative Assessment.

  • 33

    Subjective

    Qualitative assessment.

  • Cell structure.

    Cell structure.

    Quinn Karylle Fuentes · 28問 · 2年前

    Cell structure.

    Cell structure.

    28問 • 2年前
    Quinn Karylle Fuentes

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    Quinn Karylle Fuentes · 29問 · 2年前

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    29問 • 2年前
    Quinn Karylle Fuentes

    MW

    MW

    Quinn Karylle Fuentes · 45問 · 2年前

    MW

    MW

    45問 • 2年前
    Quinn Karylle Fuentes

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    Quinn Karylle Fuentes · 38問 · 2年前

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    38問 • 2年前
    Quinn Karylle Fuentes

    Density and specific gravity

    Density and specific gravity

    Quinn Karylle Fuentes · 34問 · 2年前

    Density and specific gravity

    Density and specific gravity

    34問 • 2年前
    Quinn Karylle Fuentes

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    Quinn Karylle Fuentes · 18問 · 2年前

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    18問 • 2年前
    Quinn Karylle Fuentes

    Microbial growth

    Microbial growth

    Quinn Karylle Fuentes · 63問 · 2年前

    Microbial growth

    Microbial growth

    63問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 61問 · 2年前

    Introduction.

    Introduction.

    61問 • 2年前
    Quinn Karylle Fuentes

    Microbial control.

    Microbial control.

    Quinn Karylle Fuentes · 97問 · 2年前

    Microbial control.

    Microbial control.

    97問 • 2年前
    Quinn Karylle Fuentes

    States of matter

    States of matter

    Quinn Karylle Fuentes · 100問 · 2年前

    States of matter

    States of matter

    100問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 86問 · 2年前

    Introduction.

    Introduction.

    86問 • 2年前
    Quinn Karylle Fuentes

    Drug development.

    Drug development.

    Quinn Karylle Fuentes · 77問 · 2年前

    Drug development.

    Drug development.

    77問 • 2年前
    Quinn Karylle Fuentes

    CGMP

    CGMP

    Quinn Karylle Fuentes · 9問 · 2年前

    CGMP

    CGMP

    9問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    Quinn Karylle Fuentes · 24問 · 2年前

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    24問 • 2年前
    Quinn Karylle Fuentes

    Powdered & granules

    Powdered & granules

    Quinn Karylle Fuentes · 43問 · 2年前

    Powdered & granules

    Powdered & granules

    43問 • 2年前
    Quinn Karylle Fuentes

    Capsule.

    Capsule.

    Quinn Karylle Fuentes · 24問 · 2年前

    Capsule.

    Capsule.

    24問 • 2年前
    Quinn Karylle Fuentes

    Tablets.

    Tablets.

    Quinn Karylle Fuentes · 23問 · 2年前

    Tablets.

    Tablets.

    23問 • 2年前
    Quinn Karylle Fuentes

    Calculatiom of dose

    Calculatiom of dose

    Quinn Karylle Fuentes · 66問 · 2年前

    Calculatiom of dose

    Calculatiom of dose

    66問 • 2年前
    Quinn Karylle Fuentes

    Postlab 5&6

    Postlab 5&6

    Quinn Karylle Fuentes · 29問 · 2年前

    Postlab 5&6

    Postlab 5&6

    29問 • 2年前
    Quinn Karylle Fuentes

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    Quinn Karylle Fuentes · 33問 · 2年前

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    33問 • 2年前
    Quinn Karylle Fuentes

    SEMI SOLID

    SEMI SOLID

    Quinn Karylle Fuentes · 69問 · 2年前

    SEMI SOLID

    SEMI SOLID

    69問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology

    Basic immunology

    Quinn Karylle Fuentes · 60問 · 2年前

    Basic immunology

    Basic immunology

    60問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology (2)

    Basic immunology (2)

    Quinn Karylle Fuentes · 62問 · 2年前

    Basic immunology (2)

    Basic immunology (2)

    62問 • 2年前
    Quinn Karylle Fuentes

    Transdermal

    Transdermal

    Quinn Karylle Fuentes · 44問 · 2年前

    Transdermal

    Transdermal

    44問 • 2年前
    Quinn Karylle Fuentes

    Distribution.

    Distribution.

    Quinn Karylle Fuentes · 43問 · 2年前

    Distribution.

    Distribution.

    43問 • 2年前
    Quinn Karylle Fuentes

    Infectious disease.

    Infectious disease.

    Quinn Karylle Fuentes · 65問 · 2年前

    Infectious disease.

    Infectious disease.

    65問 • 2年前
    Quinn Karylle Fuentes

    Infectious diseases (2)

    Infectious diseases (2)

    Quinn Karylle Fuentes · 79問 · 2年前

    Infectious diseases (2)

    Infectious diseases (2)

    79問 • 2年前
    Quinn Karylle Fuentes

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    Quinn Karylle Fuentes · 35問 · 2年前

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    Quinn Karylle Fuentes · 35問 · 2年前

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic ( Compressed)

    All topic ( Compressed)

    Quinn Karylle Fuentes · 30問 · 2年前

    All topic ( Compressed)

    All topic ( Compressed)

    30問 • 2年前
    Quinn Karylle Fuentes

    All topics (compressed)

    All topics (compressed)

    Quinn Karylle Fuentes · 13問 · 2年前

    All topics (compressed)

    All topics (compressed)

    13問 • 2年前
    Quinn Karylle Fuentes

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    Quinn Karylle Fuentes · 28問 · 2年前

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    28問 • 2年前
    Quinn Karylle Fuentes

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    Quinn Karylle Fuentes · 16問 · 2年前

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    16問 • 2年前
    Quinn Karylle Fuentes

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    Quinn Karylle Fuentes · 26問 · 2年前

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    26問 • 2年前
    Quinn Karylle Fuentes

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    Quinn Karylle Fuentes · 23問 · 2年前

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    23問 • 2年前
    Quinn Karylle Fuentes

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Quinn Karylle Fuentes · 35問 · 2年前

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    35問 • 2年前
    Quinn Karylle Fuentes

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    Quinn Karylle Fuentes · 20問 · 2年前

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    20問 • 2年前
    Quinn Karylle Fuentes

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    Quinn Karylle Fuentes · 33問 · 2年前

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    33問 • 2年前
    Quinn Karylle Fuentes

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    Quinn Karylle Fuentes · 37問 · 2年前

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    37問 • 2年前
    Quinn Karylle Fuentes

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    Quinn Karylle Fuentes · 23問 · 2年前

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    23問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae

    Enterobacteriaceae

    Quinn Karylle Fuentes · 35問 · 2年前

    Enterobacteriaceae

    Enterobacteriaceae

    35問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae.

    Enterobacteriaceae.

    Quinn Karylle Fuentes · 28問 · 2年前

    Enterobacteriaceae.

    Enterobacteriaceae.

    28問 • 2年前
    Quinn Karylle Fuentes

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    Quinn Karylle Fuentes · 31問 · 2年前

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    31問 • 2年前
    Quinn Karylle Fuentes

    Liquid dosage form

    Liquid dosage form

    Quinn Karylle Fuentes · 12問 · 2年前

    Liquid dosage form

    Liquid dosage form

    12問 • 2年前
    Quinn Karylle Fuentes

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    Quinn Karylle Fuentes · 44問 · 2年前

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    44問 • 2年前
    Quinn Karylle Fuentes

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    Quinn Karylle Fuentes · 22問 · 2年前

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    22問 • 2年前
    Quinn Karylle Fuentes

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    Quinn Karylle Fuentes · 40問 · 2年前

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    40問 • 2年前
    Quinn Karylle Fuentes

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    Quinn Karylle Fuentes · 29問 · 2年前

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    29問 • 2年前
    Quinn Karylle Fuentes

    Drug incompatibilities.

    Drug incompatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug incompatibilities.

    Drug incompatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    Drug compatibilities.

    Drug compatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug compatibilities.

    Drug compatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 35問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    35問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 30問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    30問 • 2年前
    Quinn Karylle Fuentes

    SUSPENSION.

    SUSPENSION.

    Quinn Karylle Fuentes · 45問 · 2年前

    SUSPENSION.

    SUSPENSION.

    45問 • 2年前
    Quinn Karylle Fuentes

    Colloidal.

    Colloidal.

    Quinn Karylle Fuentes · 40問 · 2年前

    Colloidal.

    Colloidal.

    40問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    Quinn Karylle Fuentes · 38問 · 2年前

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    38問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY.

    BACTERIOLOGY.

    Quinn Karylle Fuentes · 44問 · 2年前

    BACTERIOLOGY.

    BACTERIOLOGY.

    44問 • 2年前
    Quinn Karylle Fuentes

    Emulsion.

    Emulsion.

    Quinn Karylle Fuentes · 32問 · 2年前

    Emulsion.

    Emulsion.

    32問 • 2年前
    Quinn Karylle Fuentes

    EMULSION

    EMULSION

    Quinn Karylle Fuentes · 42問 · 2年前

    EMULSION

    EMULSION

    42問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    Quinn Karylle Fuentes · 36問 · 2年前

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    36問 • 2年前
    Quinn Karylle Fuentes

    Mycology.

    Mycology.

    Quinn Karylle Fuentes · 30問 · 2年前

    Mycology.

    Mycology.

    30問 • 2年前
    Quinn Karylle Fuentes

    Mycology 2.0

    Mycology 2.0

    Quinn Karylle Fuentes · 34問 · 2年前

    Mycology 2.0

    Mycology 2.0

    34問 • 2年前
    Quinn Karylle Fuentes

    m

    m

    Quinn Karylle Fuentes · 15問 · 2年前

    m

    m

    15問 • 2年前
    Quinn Karylle Fuentes

    ppr

    ppr

    Quinn Karylle Fuentes · 25問 · 2年前

    ppr

    ppr

    25問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    Quinn Karylle Fuentes · 20問 · 2年前

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    20問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    Quinn Karylle Fuentes · 86問 · 1年前

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    86問 • 1年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    Quinn Karylle Fuentes · 100問 · 1年前

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    100問 • 1年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    Quinn Karylle Fuentes · 19問 · 1年前

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    19問 • 1年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 17問 · 1年前

    Introduction.

    Introduction.

    17問 • 1年前
    Quinn Karylle Fuentes

    Introduction of biochemistry

    Introduction of biochemistry

    Quinn Karylle Fuentes · 76問 · 1年前

    Introduction of biochemistry

    Introduction of biochemistry

    76問 • 1年前
    Quinn Karylle Fuentes

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    Quinn Karylle Fuentes · 56問 · 1年前

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    56問 • 1年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 75問 · 1年前

    Carbohydrates

    Carbohydrates

    75問 • 1年前
    Quinn Karylle Fuentes

    Carbohydrates 1.1

    Carbohydrates 1.1

    Quinn Karylle Fuentes · 31問 · 1年前

    Carbohydrates 1.1

    Carbohydrates 1.1

    31問 • 1年前
    Quinn Karylle Fuentes

    Detect and quality variation.

    Detect and quality variation.

    Quinn Karylle Fuentes · 56問 · 1年前

    Detect and quality variation.

    Detect and quality variation.

    56問 • 1年前
    Quinn Karylle Fuentes

    INTRODUCTION

    INTRODUCTION

    Quinn Karylle Fuentes · 98問 · 1年前

    INTRODUCTION

    INTRODUCTION

    98問 • 1年前
    Quinn Karylle Fuentes

    lab (1-2)

    lab (1-2)

    Quinn Karylle Fuentes · 15問 · 1年前

    lab (1-2)

    lab (1-2)

    15問 • 1年前
    Quinn Karylle Fuentes

    lab 1-2

    lab 1-2

    Quinn Karylle Fuentes · 14問 · 1年前

    lab 1-2

    lab 1-2

    14問 • 1年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    Quinn Karylle Fuentes · 45問 · 1年前

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    45問 • 1年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    Quinn Karylle Fuentes · 35問 · 1年前

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    35問 • 1年前
    Quinn Karylle Fuentes

    Unit 3.

    Unit 3.

    Quinn Karylle Fuentes · 39問 · 1年前

    Unit 3.

    Unit 3.

    39問 • 1年前
    Quinn Karylle Fuentes

    Histamin and kinins

    Histamin and kinins

    Quinn Karylle Fuentes · 70問 · 1年前

    Histamin and kinins

    Histamin and kinins

    70問 • 1年前
    Quinn Karylle Fuentes

    PUD.

    PUD.

    Quinn Karylle Fuentes · 45問 · 1年前

    PUD.

    PUD.

    45問 • 1年前
    Quinn Karylle Fuentes

    ..

    ..

    Quinn Karylle Fuentes · 61問 · 1年前

    ..

    ..

    61問 • 1年前
    Quinn Karylle Fuentes

    Lipids.

    Lipids.

    Quinn Karylle Fuentes · 67問 · 1年前

    Lipids.

    Lipids.

    67問 • 1年前
    Quinn Karylle Fuentes

    lipids.

    lipids.

    Quinn Karylle Fuentes · 71問 · 1年前

    lipids.

    lipids.

    71問 • 1年前
    Quinn Karylle Fuentes

    LAB ✨

    LAB ✨

    Quinn Karylle Fuentes · 93問 · 1年前

    LAB ✨

    LAB ✨

    93問 • 1年前
    Quinn Karylle Fuentes

    Drug discovery.

    Drug discovery.

    Quinn Karylle Fuentes · 87問 · 1年前

    Drug discovery.

    Drug discovery.

    87問 • 1年前
    Quinn Karylle Fuentes

    disease of lipids.

    disease of lipids.

    Quinn Karylle Fuentes · 13問 · 1年前

    disease of lipids.

    disease of lipids.

    13問 • 1年前
    Quinn Karylle Fuentes

    Intro (identify structure)

    Intro (identify structure)

    Quinn Karylle Fuentes · 57問 · 1年前

    Intro (identify structure)

    Intro (identify structure)

    57問 • 1年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 98問 · 1年前

    Carbohydrates

    Carbohydrates

    98問 • 1年前
    Quinn Karylle Fuentes

    Dynamic.

    Dynamic.

    Quinn Karylle Fuentes · 96問 · 1年前

    Dynamic.

    Dynamic.

    96問 • 1年前
    Quinn Karylle Fuentes

    Unit 1

    Unit 1

    Quinn Karylle Fuentes · 32問 · 1年前

    Unit 1

    Unit 1

    32問 • 1年前
    Quinn Karylle Fuentes

    問題一覧

  • 1

    No error, capacity to cause error

    Category A.

  • 2

    Error that did not reach the patient

    Category B.

  • 3

    Error that reach the patient but unlikely to cause harm (omissions considered to reach patient)

    Category C.

  • 4

    Error that reached the patient & could have necessitated monitoring and or intervention to preclude harm

    Category D.

  • 5

    Multivitamins was not ordered on admission

    Category C.

  • 6

    Regular release metoprolol was ordered to patient instead of extended-release

    Category D.

  • 7

    Error that could have caused temporary harm - Needs treatment or intervention

    Category E.

  • 8

    Antihypertensive as inadvertently omitted from the orders.

    Category E.

  • 9

    Error that could have cause temporary harm requiring initial prolonged hospitalization

    Category F.

  • 10

    Anticoagulant such as warfarin was ordered daily when the patient takes it every other day

    Category F.

  • 11

    Error that could have resulted into permanent harm

    Category G.

  • 12

    Immunosupressant medication was unintentionally ordered at ¼ of the dose

    Category G.

  • 13

    Error that could have necessitated intervention to sustain life

    Category H.

  • 14

    Anticonvulsant therapy was inadvertently omitted

    Category H.

  • 15

    Error that could have resulted in death

    Category I.

  • 16

    Beta blocker was not re-ordered post-operatively.

    Category I.

  • 17

    This allows the person who commits the error or the person who discover the error to report it without being associated with the error.

    Anonymous self reports.

  • 18

    This is the official written legal reports of a medication error as documented by the hospital staff.

    Incident reports.

  • 19

    This results to underreporting of the errors due to punitive action that might occur due to the report

    Incident reports.

  • 20

    This involves in depth analysis of a large number of individual errors or the purpose of identifying a common cause.

    Critical incident techniques.

  • 21

    it involves an observer accompanying the person who will give the medication and witnessing the administration of each dose.

    Distinguished observation.

  • 22

    obtained directly from patient given by the patient, family members or significant others or caregivers typically cannot be directly measure.

    Subjective.

  • 23

    Measurable and not influenced by memory, emotions, or prejudice

    Objective.

  • 24

    outlines what the practitioner thinks the patient’s problem is, based upon the subjective and objective information acquired

    Assessment.

  • 25

    Involves the action that needs to be taken to resolve any problems that have been identified

    Plan.

  • 26

    includes initiating, revising, or discontinuing treatment or ordering additional diagnostic tests.

    Plan.

  • 27

    It outlines the drug, dose, dosage form, schedule, route of ad- ministration, and duration of therapy should be included

    Plan.

  • 28

    clearly state the nature of the drug-related problem(s) à types of medication-related problems. This will include medical information both subjective and objective findings that indicate a drug-related problem

    Findings.

  • 29

    includes the pharmacist’s evaluation of the current situation (i.e., the nature, extent, type, and clinical significance of the problem). This part of the note should delineate the thought process that led to the conclusion that a problem did or did not exist and that an active intervention either was or was not.

    Assessment.

  • 30

    this should reflect the actions proposed (or already performed) to resolve the drug-related problem based upon the preceding analysis

    Resolution.

  • 31

    include questioning the patient, gathering laboratory data, and performing the ongoing physical assessments necessary to determine the effectiveness of the plan implemented to assure that it results in an optimal outcome for the patient.

    Monitoring.

  • 32

    Objective.

    Quantitative Assessment.

  • 33

    Subjective

    Qualitative assessment.